Dr Charles Mullighan talks to ecancer at the ALL Assembly 2018 Meeting in Amsterdam about Latest concepts in the diagnosis of genetic ALL subtypes.
Dr Mullighan discusses that it is important to identify these new subtypes to determine how well patients respond to therapy but that there are many complications.
He also considers whether or not to carry out a single trial that encompasses most or all subtypes or alternatively a collaborative study where everyone is genotyping with some approach.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.